Issue 11, 2018

Recent strategies to improve boron dipyrromethene (BODIPY) for photodynamic cancer therapy: an updated review

Abstract

BODIPYs are photosensitizers activatable by light to generate highly reactive singlet oxygen (1O2) from molecular oxygen, leading to tissue damage in the photoirradiated region. Despite their extraordinary photophysical characteristics, they are not featured in clinical photodynamic therapy. This review discusses the recent advances in the design and/or modifications of BODIPYs since 2013, to improve their potential in photodynamic cancer therapy and related areas.

Graphical abstract: Recent strategies to improve boron dipyrromethene (BODIPY) for photodynamic cancer therapy: an updated review

Article information

Article type
Perspective
Submitted
18 Mar 2018
Accepted
11 May 2018
First published
14 May 2018

Photochem. Photobiol. Sci., 2018,17, 1691-1708

Recent strategies to improve boron dipyrromethene (BODIPY) for photodynamic cancer therapy: an updated review

C. S. Kue, S. Y. Ng, S. H. Voon, A. Kamkaew, L. Y. Chung, L. V. Kiew and H. B. Lee, Photochem. Photobiol. Sci., 2018, 17, 1691 DOI: 10.1039/C8PP00113H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements